Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 2025 Oct 29;122(44):e2526541122. doi: 10.1073/pnas.2526541122

Correction for Mittal et al., Mechanisms underlying allosteric modulation of antiseizure medication binding to synaptic vesicle protein 2A (SV2A)

PMCID: PMC12595447  PMID: 41160610

Correction for “Mechanisms underlying allosteric modulation of antiseizure medication binding to synaptic vesicle protein 2A (SV2A),” by Anshumali Mittal, Matthew F. Martin, Laurent Provins, Adrian Hall, Marie Ledecq, Christian Wolff, Michel Gillard, Peter S. Horanyi, and Jonathan A. Coleman, which published September 2, 2025; 10.1073/pnas.2510239122 (Proc. Natl. Acad. Sci. U.S.A. 122, e2510239122).

The authors note that, due to a production error, Fig. 1 appeared incorrectly. The authors note that “the updated Fig. 1 includes chemical drawings of padsevonil and UCB2500.” The corrected figure and its legend appear below. The online version has been corrected.

Fig. 1.

Fig. 1.

UCB1244283 exerts an allosteric effect on the SV2A-LEV complex. (A) Chemical structures of SV2A-specific ligands, Levetiracetam (LEV) [2S-(2-oxo-1-pyrrolidinyl) butanamide], Brivaracetam (BRV) [(2S)-2-((4R)-2-oxo-4-propylpyrrolidin-1-yl)butanamide], Padsevonil (PSL) [(4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one], UCB2500 [(4S)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]-4-(4,4,4-trifluorobutyl)pyrrolidin-2-one], and UCB1244283 [4-(3,5-dimethylphenyl)-N-(2-methoxyphenyl)-3-methylbutanamide], chiral center is shown with red circle. (B) Thermostability of mVenus-tagged SV2AΔ64 with no ligand (red), 20 µM BRV (green), 30 µM UCB1244283 (black), BRV-UCB1244283 (blue), and LEV-UCB1244283 (cyan). 100 µM LEV was used for the LEV-UCB1244283 experiment. (C) UCB1244283 (30 µM) increases the maximum specific binding (Bmax) of 3H-LEV (~4 µM) to SV2A. (D) Concentration–response curve for measuring EC50 of UC1244283 (30 μM, 15 μM, 1 μM, 100 nM, 10 nM, and 1 nM) by binding of 3H-LEV (~4 μM) to SV2A. The EC50 was calculated 0.7 ± 0.3 μM by nonlinear regression using a logarithmic concentration response sigmoidal curve. Data are shown as mean ± SEM (n = 7). (E) 3H-LEV saturation binding experiments for measuring LEV binding affinity to SV2A (Kd = 3.8 ± 0.8 μM) in presence of UCB1244283. Data are shown as mean ± SEM (n = 8).


Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES